Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adicet Bio, Inc. (ACET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Adicet uses these filings to report on its allogeneic gamma delta CAR T cell programs in autoimmune diseases and cancer, capital raising transactions, and key corporate actions.
Investors can review Form 8-K current reports in which Adicet describes material events such as preliminary Phase 1 data for ADI-001/prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, updates on enrollment across additional autoimmune indications, strategic pipeline prioritization and discontinuation of ADI-270, and development plans for the ADI-212 solid tumor program. Other 8-K filings cover registered direct offerings of common stock and pre-funded warrants, Nasdaq bid price notices and market transfers, and workforce reduction decisions.
The company’s proxy materials, such as the definitive proxy statement on Schedule 14A for a special meeting of stockholders, outline proposals including amendments to the certificate of incorporation to effect a reverse stock split within a specified range and potential adjournments to solicit additional proxies. These documents detail how stockholders can vote, participate in virtual meetings, and understand the rationale for capital structure changes.
On Stock Titan, ACET filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly identify topics such as clinical data disclosures, financing terms, reverse stock split mechanics, and listing compliance discussions. Users can also locate quarterly and annual reports when filed (Forms 10-Q and 10-K), as well as any Form 4 insider transaction reports, to build a more complete picture of Adicet Bio’s financial condition, governance, and progress in advancing its gamma delta CAR T pipeline.